The weekly litigation news digest is live. Subscribe now

IP Verse

Pharmaceutical Composition Comprising Selexipag - EP3592391

The patent EP3592391 was granted to Actelion Pharmaceuticals on Apr 21, 2021. The application was originally filed on Mar 7, 2018 under application number EP18711258A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3592391

ACTELION PHARMACEUTICALS
Application Number
EP18711258A
Filing Date
Mar 7, 2018
Status
Granted And Under Opposition
Mar 19, 2021
Publication Date
Apr 21, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSJan 12, 2022ELKINGTON AND FIFEWITHDRAWN

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO02088084
DESCRIPTIONWO2009107736
DESCRIPTIONWO2009154246
DESCRIPTIONWO2009157396
DESCRIPTIONWO2009157397
DESCRIPTIONWO2009157398
DESCRIPTIONWO2010150865
DESCRIPTIONWO2011024874
DESCRIPTIONWO2013024051
DESCRIPTIONWO2014069401
INTERNATIONAL-SEARCH-REPORTEP2893922
OPPOSITIONEP2893922
OPPOSITIONWO2010150865

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents